Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
conteltinib
- Development stage
- Phase 2
- Lead developer
- Shouyao Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Conteltinib is a potent oral multi-kinase inhibitor primarily targeting anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK), and proline-rich tyrosine kinase 2 (Pyk2). It exhibits significant inhibitory activity against FAK with an IC50 of 1.6 nM. Conteltinib has demonstrated anti-tumor activity in preclinical and clinical studies, particularly in advanced ALK-positive non-small cell lung cancer (NSCLC) and pancreatic cancer. The drug also acts as an IGF type 1 receptor antagonist. Developed as a new molecular entity by Centaurus Biopharma and partners, it is currently in phase III clinical trials for NSCLC and pancreatic cancer[1][2][3][6][8].
- Brand names
- conteltinib
- Other names
- conteltinibCT 707CT707CT-707SY 707SY707SY-707
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)FAK (Focal adhesion kinase)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)PTK2B
Beyond the preview
Go deeper on conteltinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on conteltinib.